Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques
- PMID: 15749128
- DOI: 10.1016/j.virol.2005.01.026
Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques
Abstract
Here, we evaluate the T cell responses raised by our HIV-1 clade B DNA/MVA vaccine for recognition of a HIV-1 circulating recombinant form (CRF) AG Gag sequence (CRF-02). The cross-clade activity for the AG sequence was better conserved for CD8 than CD4 T cells. CD8 T cells exhibited 75% conservation for height and 83% conservation for breadth, whereas CD4 responses exhibited 45% conservation for height and 50% conservation for breadth. Five CD8 epitopes and 8 CD4 epitopes were mapped. Three of the 5 CD8 epitopes and 2 of the 8 CD4 epitopes were conserved across multiple HIV-1 clades. Impressively, all of the CD8 epitopes and half of the CD4 epitopes have been reported for human infections. Our results demonstrate that the clade B DNA/MVA HIV vaccine elicits T cell responses against epitopes that are conserved in multiple clades and recognized by humans and macaques.
Similar articles
-
Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.AIDS Res Hum Retroviruses. 2004 Jun;20(6):654-65. doi: 10.1089/0889222041217419. AIDS Res Hum Retroviruses. 2004. PMID: 15242543
-
Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation.J Virol. 2005 Sep;79(17):11247-58. doi: 10.1128/JVI.79.17.11247-11258.2005. J Virol. 2005. PMID: 16103177 Free PMC article.
-
CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.J Virol. 2005 Jan;79(1):393-400. doi: 10.1128/JVI.79.1.393-400.2005. J Virol. 2005. PMID: 15596832 Free PMC article.
-
Multiple Approaches for Increasing the Immunogenicity of an Epitope-Based Anti-HIV Vaccine.AIDS Res Hum Retroviruses. 2015 Nov;31(11):1077-88. doi: 10.1089/AID.2015.0101. Epub 2015 Aug 13. AIDS Res Hum Retroviruses. 2015. PMID: 26149745 Review.
-
Development of a DNA-MVA/HIVA vaccine for Kenya.Vaccine. 2002 May 6;20(15):1995-8. doi: 10.1016/s0264-410x(02)00085-3. Vaccine. 2002. PMID: 11983261 Review.
Cited by
-
HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice.J Immune Based Ther Vaccines. 2010 Nov 19;8:7. doi: 10.1186/1476-8518-8-7. J Immune Based Ther Vaccines. 2010. PMID: 21087527 Free PMC article.
-
Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.J Infect Dis. 2017 Nov 27;216(9):1080-1090. doi: 10.1093/infdis/jix456. J Infect Dis. 2017. PMID: 28968759 Free PMC article.
-
Design and pre-clinical evaluation of a universal HIV-1 vaccine.PLoS One. 2007 Oct 3;2(10):e984. doi: 10.1371/journal.pone.0000984. PLoS One. 2007. PMID: 17912361 Free PMC article.
-
DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge.Virology. 2007 Sep 15;366(1):73-83. doi: 10.1016/j.virol.2007.04.010. Epub 2007 May 16. Virology. 2007. PMID: 17507071 Free PMC article.
-
Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate.J Biol Chem. 2015 Apr 3;290(14):9195-208. doi: 10.1074/jbc.M114.621185. Epub 2015 Feb 17. J Biol Chem. 2015. PMID: 25691567 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials